<DOC>
	<DOCNO>NCT01389466</DOCNO>
	<brief_summary>This study design two step Step 1 , single-center , double-blind , randomize clinical Pilot study Step 2 , multi-center , single-blind , randomize clinical Pivotal study . The investigator evaluate immunogenicity safety investigational vaccine subject participation study .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity MG1109 Healthy Adult Volunteers</brief_title>
	<detailed_description>MG1109 purify , inactivate influenza viral antigen .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Healthy adult available followup study Subjects history exposure H5N1 subtype H5N1 subtype vaccine Subjects immune system disorder include immune deficiency disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Avian influenza</keyword>
</DOC>